Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$167.6m

Regulus Therapeutics Management

Management criteria checks 4/4

Regulus Therapeutics' CEO is Jay Hagan, appointed in May 2017, has a tenure of 6.92 years. total yearly compensation is $1.34M, comprised of 44.5% salary and 55.5% bonuses, including company stock and options. directly owns 0.087% of the company’s shares, worth $146.21K. The average tenure of the management team and the board of directors is 4.7 years and 6.9 years respectively.

Key information

Jay Hagan

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage44.5%
CEO tenure6.9yrs
CEO ownership0.09%
Management average tenure4.7yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Regulus Therapeutics GAAP loss per share narrows

Aug 11

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

The Read On Regulus Therapeutics

Aug 03

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

CEO Compensation Analysis

How has Jay Hagan's remuneration changed compared to Regulus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$30m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$598k

-US$28m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$568k

-US$28m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$15m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$2mUS$552k

-US$16m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$23m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$2mUS$536k

-US$19m

Sep 30 2019n/an/a

-US$22m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$36m

Dec 31 2018US$2mUS$520k

-US$49m

Sep 30 2018n/an/a

-US$55m

Jun 30 2018n/an/a

-US$60m

Mar 31 2018n/an/a

-US$68m

Dec 31 2017US$2mUS$475k

-US$72m

Compensation vs Market: Jay's total compensation ($USD1.34M) is about average for companies of similar size in the US market ($USD1.60M).

Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.

CEO

Jay Hagan (54 yo)

6.9yrs

Tenure

US$1,343,238

Compensation

Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Hagan
CEO & Director6.9yrsUS$1.34m0.087%
$ 146.2k
Crispina Calsada
Chief Financial Officer4.7yrsUS$627.62k0.00024%
$ 402.2
Christopher Aker
Senior VP13.2yrsUS$651.54k0.015%
$ 25.7k
Preston Klassen
Presidentless than a yearno datano data
Daniel Penksa
VP of Finance & Controller4.8yrsno datano data
Claire Padgett
Senior Vice President of Clinical Operations1.4yrsno datano data
Rekha Garg
Senior Vice President of Clinical Development & Regulatory1.4yrsno datano data
Edmund Lee
Vice President of Translational Medicineno datano datano data

4.7yrs

Average Tenure

54yo

Average Age

Experienced Management: RGLS's management team is considered experienced (4.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Hagan
CEO & Director6.9yrsUS$1.34m0.087%
$ 146.2k
Preston Klassen
Presidentless than a yearno datano data
William Rastetter
Independent Director11yrsUS$70.77k0.060%
$ 100.0k
Timothy Wright
Member of the Scientific Advisory Board5.1yrsUS$1.48mno data
Stelios Papadopoulos
Independent Chairman of the Board15.3yrsUS$102.77k1.49%
$ 2.5m
David Baltimore
Chairman of the Scientific Advisory Board & Independent Director15.3yrsUS$66.77k0.0039%
$ 6.6k
Jason Nunn
Independent Director4.8yrsUS$68.77k0%
$ 0
Thomas Tuschl
Member of the Scientific Advisory Boardno datano datano data
Markus Stoffel
Member of the Scientific Advisory Boardno datano datano data
Hugh Rosen
Independent Director7.8yrsUS$64.77k0.0027%
$ 4.5k
Kathryn Collier
Independent Director6yrsUS$78.77k0.0042%
$ 7.0k
Pascale Witz
Independent Director6.8yrsUS$64.77k0.0072%
$ 12.1k

6.9yrs

Average Tenure

60yo

Average Age

Experienced Board: RGLS's board of directors are considered experienced (6.9 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.